Centessa Pharmaceuticals (CNTA) Stock Price, Quote, News & History

Comments

Centessa Pharmaceuticals PLC (CNTA) Stock Price, Quote, News & History

CNTANASDAQ

Trade with Public

$39.72

12.1444.02%

At close: Mar 30, 5:00 PM EST

$39.80

12.2244.31%

Pre-Market: 8:00 AM EST

PRO

Why Is It Moving?™:Eli Lilly Expands Into Sleep Medicine With Centessa Buyout

M&A: Centessa Pharmaceuticals (CNTA) announced it will be acquired by Eli Lilly (LLY) on Tuesday, March 31, 2026

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

-

Close

$39.72

Volume / Avg.

4.75K / 2.17M

Day Range

- - -

52 Wk Range

9.60 - 40.26

Market Cap

$5.88B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

78

Short Interest

5.19%

Days to Cover

4.68

Recent Centessa Pharmaceuticals PLC News

Eli Lilly Expands Into Sleep Medicine With Centessa Buyout

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.

Vandana Singh

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

Vishaal Sanjay

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-180.81M

Investing Cash Flow (TTM)

-175.40M

Financing Cash Flow (TTM)

11.09M

Free Cash Flow (TTM)

-181.17M

Capital Expenditure (TTM)

-360.00K

Net Change in Cash (TTM)

-345.12M

Analyst Trends and Forecast

2

Dec 25

3

Jan

1

Feb

0

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.74B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

352.53

PB Ratio (TTM)

19.45

Earnings Yield % (TTM)

-4.76%

Earnings Yield % (FWD)

-4.13%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.04

Company Debt

Total Debt

$109.82M

LT Debt

$109.82M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$50.81M

Debt to Equity

0.39

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$39.72

Volume / Avg.

4.75K / 2.17M

Day Range

- - -

52 Wk Range

9.60 - 40.26

Market Cap

$5.88B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

78

Short Interest

5.19%

Days to Cover

4.68

About

Sector

Health Care

Industry

Biotechnology

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arter...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Centessa Pharmaceuticals (CNTA) stock?

A

You can purchase shares of Centessa Pharmaceuticals (NASDAQ:CNTA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Centessa Pharmaceuticals (CNTA) competitors?

A

Other companies in Centessa Pharmaceuticals’s space includes: Immunovant Inc (NASDAQ:IMVT), Cogent Biosciences Inc (NASDAQ:COGT), Celcuity Inc (NASDAQ:CELC), Alkermes PLC (NASDAQ:ALKS) and Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Q

What is the forecast, or price target, for Centessa Pharmaceuticals (CNTA) stock?

A

Centessa Pharmaceuticals has a consensus price target of $29.67.

Q

What is the current price for Centessa Pharmaceuticals (CNTA)?

A

The stock price for Centessa Pharmaceuticals (NASDAQ: CNTA) is $39.8 last updated April 1, 2026 at 7:59 AM EDT.

Q

Does Centessa Pharmaceuticals (CNTA) pay a dividend?

A

There are no upcoming dividends for Centessa Pharmaceuticals.

Q

When is Centessa Pharmaceuticals (NASDAQ:CNTA) reporting earnings?

A

Centessa Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Centessa Pharmaceuticals (CNTA) going to split?

A

There is no upcoming split for Centessa Pharmaceuticals.

Q

What sector and industry does Centessa Pharmaceuticals (CNTA) operate in?

A

Centessa Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Cogent Biosciences Inc

Xenon Pharmaceuticals Inc

Protagonist Therapeutics Inc

Key Statistics

Open

-

Close

$39.72

Volume / Avg.

4.75K / 2.17M

Day Range

- - -

52 Wk Range

9.60 - 40.26

Market Cap

$5.88B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

78

Short Interest

5.19%

Days to Cover

4.68

Recent Centessa Pharmaceuticals PLC News

Eli Lilly Expands Into Sleep Medicine With Centessa Buyout

Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.

Vandana Singh

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

Vishaal Sanjay

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-180.81M

Investing Cash Flow (TTM)

-175.40M

Financing Cash Flow (TTM)

11.09M

Free Cash Flow (TTM)

-181.17M

Capital Expenditure (TTM)

-360.00K

Net Change in Cash (TTM)

-345.12M

Analyst Trends and Forecast

2

Dec 25

3

Jan

1

Feb

0

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.74B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

352.53

PB Ratio (TTM)

19.45

Earnings Yield % (TTM)

-4.76%

Earnings Yield % (FWD)

-4.13%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.04

Company Debt

Total Debt

$109.82M

LT Debt

$109.82M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$50.81M

Debt to Equity

0.39

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$39.72

Volume / Avg.

4.75K / 2.17M

Day Range

- - -

52 Wk Range

9.60 - 40.26

Market Cap

$5.88B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

78

Short Interest

5.19%

Days to Cover

4.68

About

Sector

Health Care

Industry

Biotechnology

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arter...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry